Abstract

The enclosed application represents the development of a consortium of investigators who will carry out multicenter drug trials in Alzheimer's disease (AD). This consortium, containing 30 Alzheimer Disease Study Units (ADSUs), will critically examine existing instruments for the evaluation of AD patients participating in clinical drug trials. When appropriate, new instruments will be developed for use by this group. Specific drug trials proposed are a pilot study to examine the safety of nerve growth factor administered to a small number of AD patients. If safe, a multicenter double-blind, parallel, placebo-controlled trial examining both short- and long-term administration of nerve growth factor in 150 subjects is proposed. A second study examining the ability of deprenyl, a selective monoamine oxidase-B inhibitor, to slow the rate of decline in AD is also proposed. The second study will be a two-year, parallel, double-blind, placebo-controlled trial in 300 subjects. Additional drug trials are proposed for Years 4 and 5 of this grant. The specific drug trials included in this proposal are examples of trials that might be carried out by this consortium. Final decisions regarding which drugs are tested will be made in consultation with NIA and the NIA-appointed Oversight Committee.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AG010483-02
Application #
3546483
Study Section
Neuroscience, Behavior and Sociology of Aging Review Committee (NBSA)
Project Start
1991-09-30
Project End
1996-06-30
Budget Start
1992-07-15
Budget End
1993-06-30
Support Year
2
Fiscal Year
1992
Total Cost
Indirect Cost

  Institution

Name
University of California San Diego
Department
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093

  Publications

Rockenstein, Edward; Ostroff, Gary; Dikengil, Fusun et al. (2018) Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies. J Neurosci 38:1000-1014
Edmonds, Emily C; Ard, M Colin; Edland, Steven D et al. (2018) Unmasking the benefits of donepezil via psychometrically precise identification of mild cognitive impairment: A secondary analysis of the ADCS vitamin E and donepezil in MCI study. Alzheimers Dement (N Y) 4:11-18
Chen, Yun-Fei; Ni, Xiao; Fleisher, Adam S et al. (2018) A simulation study comparing slope model with mixed-model repeated measure to assess cognitive data in clinical trials of Alzheimer's disease. Alzheimers Dement (N Y) 4:46-53
Jacobs, Diane M; Ard, M Colin; Salmon, David P et al. (2017) Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimers Dement (N Y) 3:531-535
Moussa, Charbel; Hebron, Michaeline; Huang, Xu et al. (2017) Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease. J Neuroinflammation 14:1
Sims, Rebecca (see original citation for additional authors) (2017) Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nat Genet 49:1373-1384
El-Agnaf, Omar; Overk, Cassia; Rockenstein, Edward et al. (2017) Differential effects of immunotherapy with antibodies targeting ?-synuclein oligomers and fibrils in a transgenic model of synucleinopathy. Neurobiol Dis 104:85-96
Jun, Gyungah R; Chung, Jaeyoon; Mez, Jesse et al. (2017) Transethnic genome-wide scan identifies novel Alzheimer's disease loci. Alzheimers Dement 13:727-738
Tarrant, Sarah D; Bardach, Shoshana H; Bates, Kendra et al. (2017) The Effectiveness of Small-group Community-based Information Sessions on Clinical Trial Recruitment for Secondary Prevention of Alzheimer's Disease. Alzheimer Dis Assoc Disord 31:141-145
Kennedy, Richard E; Cutter, Gary R; Wang, Guoqiao et al. (2017) Challenging Assumptions About African American Participation in Alzheimer Disease Trials. Am J Geriatr Psychiatry 25:1150-1159

Showing the most recent 10 out of 294 publications